Avadel Pharmaceuticals Q3 EPS $(0.24) Beats $(0.27) Estimate, Sales $14.229M Beat $10.25M Estimate

Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 63.08 percent increase over losses of $(0.65) per share

Benzinga · 11/12/2019 12:48

Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 63.08 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $14.229 million which beat the analyst consensus estimate of $10.25 million by 38.82 percent. This is a 28.23 percent decrease over sales of $19.826 million the same period last year.